Transmedics Group Inc (TMDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.11 is considered Undervalued compared with the five-year average of -7.75. The fair price of Transmedics Group Inc (TMDX) is between 646.95 to 857.54 according to relative valuation method. Compared to the current price of 147.00 USD , Transmedics Group Inc By Undervalued By 77.28%.

Relative Value

Fair Zone

646.95-857.54

Current Price：147.00

77.28%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Transmedics Group Inc (TMDX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Transmedics Group Inc (TMDX) has a current Price-to-Book (P/B) ratio of 11.79. Compared to its 3-year average P/B ratio of 16.39, the current P/B ratio is approximately -28.05% higher. Relative to its 5-year average P/B ratio of 14.25, the current P/B ratio is about -17.25% higher. Transmedics Group Inc (TMDX) has a Forward Free Cash Flow (FCF) yield of approximately 2.88%. Compared to its 3-year average FCF yield of -3.09%, the current FCF yield is approximately -193.16% lower. Relative to its 5-year average FCF yield of -3.63%, the current FCF yield is about -179.30% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TMDX competitors is 100.73, providing a benchmark for relative valuation. Transmedics Group Inc Corp (TMDX.O) exhibits a P/S ratio of 6.11, which is -93.93% above the industry average. Given its robust revenue growth of 32.18%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TMDX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TMDX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TMDX currently overvalued or undervalued?

What is Transmedics Group Inc (TMDX) fair value?

TMDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Transmedics Group Inc (TMDX) is between 646.95 to 857.54 according to relative valuation method.

How does TMDX's valuation metrics compare to the industry average?

The average P/S ratio for TMDX's competitors is 100.73, providing a benchmark for relative valuation. Transmedics Group Inc Corp (TMDX) exhibits a P/S ratio of 6.11, which is -93.93% above the industry average. Given its robust revenue growth of 32.18%, this premium appears sustainable.

What is the current P/B ratio for Transmedics Group Inc (TMDX) as of Mar 03 2026?

As of Mar 03 2026, Transmedics Group Inc (TMDX) has a P/B ratio of 11.79. This indicates that the market values TMDX at 11.79 times its book value.

What is the current FCF Yield for Transmedics Group Inc (TMDX) as of Mar 03 2026?

As of Mar 03 2026, Transmedics Group Inc (TMDX) has a FCF Yield of 2.88%. This means that for every dollar of Transmedics Group Inc's market capitalization, the company generates 2.88 cents in free cash flow.

What is the current Forward P/E ratio for Transmedics Group Inc (TMDX) as of Mar 03 2026?

As of Mar 03 2026, Transmedics Group Inc (TMDX) has a Forward P/E ratio of 47.80. This means the market is willing to pay $47.80 for every dollar of Transmedics Group Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Transmedics Group Inc (TMDX) as of Mar 03 2026?

As of Mar 03 2026, Transmedics Group Inc (TMDX) has a Forward P/S ratio of 6.11. This means the market is valuing TMDX at $6.11 for every dollar of expected revenue over the next 12 months.

TMDX Valuation